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Abstract: There are still concerns about masseteric bulging due to a lack of knowledge about the
internal architecture of the masseter muscle. Further investigations are therefore required of the
most-effective botulinum neurotoxin injection points and strategies for managing masseteric bulging.
The purpose of this study was to identify safer and more effective botulinum neurotoxin injection
points and strategies by using ultrasonography to determine the structural patterns of the deep
inferior tendon. We also measured the precise depths and locations of the deep inferior tendon of the
masseter muscle. Thirty-two healthy volunteers participated in this study, and ultrasonography was
used to scan the masseter muscle both longitudinally and transversely. Three structural patterns of
the deep inferior tendon were identified: in type A, the deep inferior tendon covered the anterior
two-thirds of the masseter muscle (21.8%); in type B, the deep inferior tendon covered the posterior
two-thirds of the masseter muscle (9.4%); and in type C, the deep inferior tendon covered most of
the inferior part of the masseter muscle (68.8%). Depending on the ultrasonography scanning site,
the depth from the skin surface to the mandible in the masseteric region ranged from 15 to 25 mm.
The deep inferior tendon was typically located 2 to 5 mm deep from the mandible. Ultrasonography
can be used to observe the internal structure of the masseter muscle including the deep inferior
tendon in individual patients. This will help to reduce the side effects of masseteric bulging when
applying retrograde or dual-plane injection methods depending on the structural pattern of the deep
inferior tendon.
Keywords: ultrasonography; botulinum neurotoxin injection; masseter muscle; masseteric hypertro-
phy; clinical guideline
Key Contribution: The deep inferior tendon was observed at a similar depth in the anterior-to-
posterior direction, and from the superior to inferior directions it gradually attached to the bone and
to the inferior border of the mandible.
1. Introduction
There is a worldwide tendency of smooth facial lines and a slim jawline being desir-
able in females, which has resulted in botulinum neurotoxin (BoNT) injections for facial
contouring being widely performed ever since this procedure was introduced by Moore in
1994 [1–3]. In particular, a hypertrophied masseter muscle is commonly treated in Asians
due to the face being more angular than that of Caucasians. The shape of the Caucasian
face is narrow compared to that of Asians. Accordingly, a squared jaw is considered more
of a major aesthetic issue among Asians than among Caucasians. Angled jawlines are not
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considered attractive among Asians, especially in young women [4]. For this reason, many
previous studies have conducted research to demonstrate the effectiveness of botulinum
toxin injections into the masseter muscle in young Asians aged between 20 and 30 [5,6].
The masseter muscle is situated on the lateral side of the face and works strongly
with the temporalis muscle during mastication. The lower one-third of the masseter
muscle is known to be its thickest part [4]. The conventional BoNT injection technique
for the masseter muscle involves performing a deep injection after touching the bone of
the mandible, primarily into the lower part [5,7,8]. While BoNT treatment is valuable for
alleviating facial asymmetry and nasal flare [9] or facial rhytids of the upper, middle and
lower regions of the face [10–13], several iatrogenic side effects are frequently reported.
Avoiding these side effects requires that practitioners have a thorough understanding of
the anatomical locations and morphology of the masseter muscle, the relationship between
the masseter and risorius muscle, and related vascular structures [14–18]. Masseteric
bulging is another side effect, which is observed in 0.49~18.8% of cases and can often
occur 2–4 weeks after a BoNT injection [18–20]. If the paradoxical masseteric bulging does
not recuperate within two weeks, a superficial BoNT injection into the masseter muscle is
usually performed [18]. The presence of an abnormal facial expression is another side effect,
which is observed in 15~27.3% of cases and which is due to the overspreading of the toxin
to the risorius muscle, which is next to the anterior part of the masseter muscle [18,21].
Masseteric bulging can be managed with an additional injection of BoNT, and it
usually disappears within 12 weeks. However, frequent BoNT injections result in the
production of antibodies that reduce the treatment’s efficacy [22–24]. Therefore, various
clinical studies have been performed with the aim of identifying BoNT injection points that
would avoid masseteric bulging and increase the durability of the treatment effects [20].
These studies of BoNT injections into the masseter muscle have focused on volume changes
of the masseter muscle, as evaluated by ultrasonography (US), three-dimensional laser
scanning, computed tomography and magnetic resonance imaging (MRI). All of these
studies found that injecting BoNT into the masseter muscle was effective for aesthetic
purposes. However, there are remaining concerns about masseteric bulging and other
side effects due to a lack of knowledge about the internal architecture of the masseter
muscle. Further investigations of the most effective BoNT injection points and strategies
for managing masseteric bulging are therefore required.
The deep inferior tendon (DIT) of the masseter muscle is located within its superficial
part. The previous cadaveric and ultrasonographic study revealed that there were no
significant differences between both the male and female DIT morphologies and the right
and left sides. However, the most common pattern was different between Korean and Thai
cadaveric specimens.
The DIT blocks the BoNT from spreading evenly throughout the superficial masseter
muscle, and this tendon can be easily observed in US imaging. Masseteric bulging can be
prevented by performing a US-guided injection to accurately locate the depth of the DIT of
the masseter muscle.
US can also be used to visualize internal anatomical structures in real time. Although
US is less commonly used in the facial area, it is often used for observing masticatory
muscles when diagnosing bruxism and temporomandibular joint diseases. Numerous
recent clinical and cadaveric studies have investigated the anatomical morphology of the
temporomandibular joint and masseter muscle [19,20,25,26].
The purpose of the present study was to identify safer and more effective BoNT
injection points and strategies by using US to determine the structural patterns of the DIT,
and compare the findings with those from a previous cadaveric study. We also measured
the precise depths and locations of the DIT of the masseter muscle.
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2. Results
2.1. Types of DIT in Healthy Young Subjects
US images of the DIT of the masseter muscle were obtained in all subjects on both
sides. The structural patterns of the DIT were classified into three different types. Type A
covered reference lines b and c (anterior two-thirds of the masseter muscle); type B covered
reference lines c and d (posterior two-thirds of the masseter muscle); and type C covered
reference lines b, c and d (most of the inferior part of the masseter muscle). Figure 1 shows
example images of DITs with structural patterns of types A (21.8%, n = 7), B (9.4%, n = 3)
and C (68.8%, n = 22). The DIT could be detected more easily on longitudinal images than
transverse images. The classification into the three tendon types did not differ significantly
with sex, age, or left and right sides.
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2.2. Depth at Each Reference Line 
Figure 1. Transverse US images showing the three patterns of the DIT. US images of (A) types A,
(B) B and (C) C. (b) The line halfway between the anterior border of the masseter muscle and line c,
(c) the line halfway between the anterior and posterior borders of the masseter muscle, and (d) the line
halfway between line c and posterior border of the masseter muscle. The yellow dashed lines indicate
the depth from the skin surface to the mandible. L, lateral; P, posterior; orange arrowheads, DIT.
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2.2. Depth at Each Reference Line
The depths of the DIT at the various reference lines are presented in Figure 2 and Table
1. The DIT tended to be more deeply located in an inferior direction and more superficially
in a superior direction. However, the DIT maintained a constant depth transversely in the
anterior-to-posterior direction of the masseter muscle (Figure 2).
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Table 1. Depths (in millimeters) from the skin surface to the mandible and from the DIT (deep inferior tendon) to the
mandible on the left and right sides.
2 (n = 32) 3 ( n = 32)
Skin to DIT DIT to Mandible Skin to DIT DIT to Mandible
Right Left Right Left Right Left Right Left
b 20.9 ± 2.0 20.3 ± 1.9 4.2 ± 2.4 4.5 ± 1.9 18.0 ± 2.8 17.7 ± 2.4 3.3 ± 1.4 2.2 ± 0.3
c 20.2 ± 2.2 20.1 ± 1.9 3.9 ± 1.8 4.5 ± 2.4 17.5 ± 2.7 16.9 ± 2.1 3.2 ± 1.8 2.4 ± 1.5
d 18.5 ± 2.2 18.2 ± 2.4 3.2 ± 1.5 3.5 ± 1.0 16.1 ± 2.5 15.3 ± 1.9 4.6 ± 1.9 3.9 ± 2.3
2, the line halfway between the inferior margins of the zygomatic arch and of the masseter muscle; 3, the line halfway between line 2
and the inferior margin of the mandible; b, the line halfway between the anterior border of the masseter muscle and line c; c, the line
halfway between the anterior and posterior borders of the masseter muscle; d, the line halfway between line c and the posterior border of
the masseter muscle.
Depending on the US scanning site, the depth from the skin surface to the mandible
in the masseteric region ranged from 15 to 20 mm. The DIT was typically located 2 to
4 mm deep from the mandible. The DIT was found to be located about 5 mm above
the bone surface within the masseter muscle, that is, closer to the mandible than to the
skin (Figure 3).
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Figure 3. Layer-by-layer depiction of the masseter muscle showing the superficial belly (SB) and deep belly (DB) of the
superficial part of the masseter including the deep inferior tendon (DIT). The masseter muscle was cut at the midpoint level
between the inferior margins of the zygomatic arch origin and the masseter muscle. (A) The DIT divides the superficial part
of the masseter muscle into two layers. (B) The SB of the superficial part of the masseter muscle is partially removed to
reveal the DIT. (C) The DB of the superficial part of the masseter muscle is revealed after removing the DIT. The DIT was
present about 5 mm above the bone surface within the masseter muscle. Retrograde, dual-plane or US-guided injection
methods (depending on the type of DIT) would reduce the side effects of masseteric bulging.
3. Discussion
The present study used US to verify the structural patterns of the DIT of the masseter
muscle in healthy young volunteers and compared the findings with those obtained in
previous cadaver dissections. Performing US scanning at the same sites as in the cadaveric
study has clearly revealed the structural patterns of the DIT. Furthermore, the structural
pattern of the DIT was classified into three types: Type A covered references lines b and
c (anterior two-thirds of the masseter muscle); type B covered reference lines c and d
(posterior two-thirds of the masseter muscle); and type C covered reference lines b, c and d
(most of the inferior part of the masseter muscle) (Figure 1).
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The previous cadaveric study classified the structural patterns of the DIT into three
different types, and similar results were obtained using US [19]. The DIT could be visual-
ized in all subjects, while there were variations in the position of the DIT relative to the
reference lines. The DIT was observed at reference lines b and c in 21.8% of the specimens
(n = 7). While the patterns with reference lines b and c were the least common, in these
cases the reference line b should be carefully considered since it is adjacent to the anterior
border of the masseter muscle. The anterior border of the masseter coincides with the
risorius muscle, which may be located superficially. Consequently, superficial injections
into the anterior border area should be performed with the utmost care in order to prevent
side effects of changes in the facial muscles due to damage to the risorius. The patterns
in which reference lines c and d were covered constituted 9.4% of the specimens (n = 3).
Reference line d was adjacent to the parotid gland, and any spread of the BoNT to this
gland can cause xerostomia or dry mouth. The reported incidence rate for xerostomia is
6.3–13.3%, and the recovery time is typically 3–4 weeks [4,16]. Particular care is therefore
recommended when injecting into the posterior part of the masseter muscle, which is the
location of reference line d and which is where the parotid gland is located superficial to
the masseter muscle. The most common pattern was that where reference lines b, c and d
were covered, which was where the superficial part of the masseter muscle divided into the
superficial and deep muscle bellies. This pattern was observed in 68.8% of the specimens
(n =22) and was also the most common pattern that was found in the previous cadaveric
study of Korean specimens [20]. Since the DIT divides the superficial part of the masseter
muscle into two layers, dual-plane and retrograde injections would be advantageous for
preventing masseter bulging.
A consideration of both injection points and depths is crucial to obtaining positive
outcomes of masseteric BoNT treatments. Several previous studies have evaluated the
durability and formation of the antibodies in the muscle, but they did not reveal the
detailed depths of the structures of the masseter muscle, such as of the masseter muscle
itself and the DIT. In the present study, the DIT was found at reference lines 2 and 3 of the
masseter muscle. At reference line 2, the DIT was generally positioned at a constant depth
in the anterior-to-posterior direction. The observations for reference line 3 were similar to
those for reference line 2, with the DIT being close to the mandible. Therefore, the depth of
the DIT could be estimated as being within 25% of the deeper area of the entire masseter
muscle at reference lines 2 and 3. The entire pattern of the DIT could be readily observed
in transverse US images as a hyperechoic structure, while longitudinal US images were
better for observing the entire presence of the DIT with the masseter muscle.
Various studies have investigated how the intramuscular nerve distribution of the
masseter muscle [27], the course of the marginal mandibular branch of the facial nerve [28],
and the location, morphology and proportion of the DIT affect the efficacy of injecting BoNT
into the masseter muscle [19]. Cioffi et al. reported that the masseter muscle consisted
of several aponeuroses that attached to the muscle as a lamellar-like structure, based on
observations made using MRI [29]. The present study found that the DIT was present only
as a single tendon rather than multiple tendinous structures, as in most cases. However, in
some cases the DIT did have more than two tendinous structures. The discrepancy with the
description obtained from the previous cadaveric study of Lee et al. [20] is attributable to
the use of different research materials and methods. The previous study dissected cadavers
and showed only the two-dimensional plane structure of the DIT of the masseter muscle.
In contrast, three-dimensional observations are possible using MRI and US. Although in
most of the present cases the DIT was observed as a single tendon entering the masseter
muscle, the use of US-guided BoNT injections would be helpful for preventing masseteric
bulging by confirming the DIT pattern in patients who have multiple DITs.
Previous studies revealed that the internal architecture of the masseter muscle, includ-
ing the muscle thickness and tendinous structure, varied in the dentate and edentulous
group. However, there was no statistical difference between the internal structure of the
masseter muscle and age [30]. In addition, our previous studies demonstrated a very
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similar internal architecture of the masseter muscle between the elderly cadavers and the
younger subjects via US [20]. Therefore, the internal architecture of the muscle could be
observed as being the same structure within elderly and young age groups. The use of the
US is recommended for building patient-specific treatment strategies and/or preventing
iatrogenic side effects such as paradoxical masseteric bulging.
Although the present study demonstrated that the internal architecture of the masseter
muscle (i.e., DIT, which is helpful when treating BoNT injections in young adults aged
approximately 20 to 30), further studies with a larger sample size of various age groups
(including elderly ones) are required to build patient-customized treatment strategies for
each age group.
4. Conclusions
The DIT was observed at a similar depth in the anterior-to-posterior direction, and
from the superior to inferior directions it gradually attached to the bone and to the inferior
border of the mandible. The DIT was present within 25% of the entire masseter muscle
or 5-mm-deep relative to it. In addition, in some cases more than one DIT was observed.
Based on this complexity of the structural patterns of the DIT, we believe that US is useful
for observing the internal structure of the masseter muscle, including the DIT, in individual
patients in real time and will thereby help reduce the side effects of masseteric bulging
when applying retrograde or dual-plane injection methods depending on the type of DIT
that is encountered.
5. Materials and Methods
All of the experimental procedures in this study were performed in accordance with
the Declaration of Helsinki of the World Medical Association (version of October 2013).
The research was approved by the Institutional Review Board of the Yonsei University
Dental Hospital (Approval No. 2-2019-0026, granted on 30 July 2019). A real-time two-
dimensional B-mode US system (ECUBE 15, ALPINION Medical Systems, Seoul, Korea)
with a 60-mm-wide linear-array transducer (3.0–15.0 MHz; L8-17X, ALPINION Medical
Systems) was used to obtain US images of the masseter muscle in healthy young subjects.
While numerous studies have been conducted to elucidate the efficacy of botulinum
toxin injection into the masseter muscle, there have been no studies that systematically
investigated the age of patients who received botulinum toxin treatment for aesthetic
purposes. However, based on previous research that was conducted on a similar topic to
this study, most patients were in their 20s [5,6,18]. Therefore, the young age group was
selected for the present study.
US Scanning of Healthy Young Subjects
Signed written informed consents were obtained from 32 healthy young subjects [16
males and 16 females aged 25.4 ± 4.1 years (mean ± SD)]. The exclusion criteria were
orthodontic treatment, temporomandibular joint disorder, plastic surgery or receiving a
BoNT injection within the previous six months. The subjects were asked to clench their
jaws to ensure that the precise anterior and posterior borders of the masseter muscle could
be identified prior to performing US scanning. Longitudinal and transverse reference lines
were defined for the US imaging of the masseter muscle (Figure 4). The following five
longitudinal reference lines were defined:
a. The anterior border of the masseter muscle.
b. The line halfway between lines a and c.
c. The line halfway between lines a and e.
d. The line halfway between lines c and e.
e. The posterior border of the masseter muscle.
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Figure 4. Ultrasonography (US) scanning sites. (A) Longitudinal section scanning was performed along reference lines b, c
and d of the masseter muscle, while (B) transverse section scanning was performed along reference lines 2 and 3. There
were five longitudinal reference lines: (a) the anterior border of the masseter muscle, (b) the line halfway between lines a
and c, (c) the line halfway between lines a and e, (d) the line halfway between lines c and e, and (e) the posterior border of
the masseter muscle. There were four transverse reference lines: (1) the line halfway between the inferior margin of the
zygomatic arch and line 2, (2) the line halfway between the inf rior margin of the zygomatic arch and line 4, (3) the line
halfway between lines 2 and 4, and (4) the inferior margin of the mandible.
The following four transverse reference lines were defined:
1. The line halfway between the inf rior margin of the zygomatic arch and line 2.
2. The line halfway between the inferior margin f the zygomatic arch and line 4.
3. The line halfway between lines 2 and 4.
4. The inferior margin of the mandible.
The US sampling frequency was set to 15.0 MHz, which is an ideal frequency for
observing de ths between 2.5 and 4 cm dep nding on the pres nce of skin, fat and muscle
tissues. A water-soluble gel was applied to the skin to optimize th acquisitio of images
and prevent artifacts. The US transducer was positio ed perpendicularly to the skin surface
ver the rea of the masseter muscl . The imaging was performed on both sides of the fac .
The DIT of the mass ter muscle and its location were confirmed by cross-ch cking between
the transverse and longitudinal US images.
The morph logy of the DIT w s classified based on the previous cadaveric study that
divided the tendon into three types. Types A, B and C covered references lines b and c
(anterior two-thirds of the masseter muscle), reference lines c and d (posterior two-thirds
of the masseter muscle), and reference lines b, c and d (most of the inferior part of the
masseter muscle), respectively. The depths from the skin to the mandible and from the
mandible to the DIT at each reference line were measured using Image J software (National
Institutes of Health, Bethesda, MD, USA) (Figure 5).
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